CiRA

CiRA OPEN SEMINAR SERIES

# PROMISE AND CHALLENGE OF VECTORED THERAPIES: A CDMO PERSPECTIVE

## PHILIP WILLS, PH.D.

CHIEF COMMERCIAL OFFICER
CATALENT CELL AND GENE THERAPY

Viral vector-based cell and gene therapies continue to advance at breakneck speed. The last year alone saw the approval of the first-ever CRISPR technology (sickle cell disease) as well as approvals for Duchenne Muscular Dystrophy and Hemophilia A. Hundreds of cell and gene therapy clinical trials are underway, ensuring a rich pipeline for years to come. This discussion will overview significant innovations in the field, such as engineered and novel capsids, which may permit lower dosing and reduced toxicity, as well as strategies to address immune challenges and off-target effects. COGS (cost of goods sold) remains a key challenge, in part addressed by improved tissue targeting, in addition to significant improvements in starting materials, including engineered plasmids and clonally selected production cell lines. Lastly, platform strategies enable a rapid and templated approach to first-in-human clinical studies while smoothing the path for late-stage clinical and commercial release.

*Philip Wills, Chief Commercial Officer at Catalent Cell & Gene Therapy, is a veteran business executive and scientist with nearly two decades of contract manufacturing experience, primarily focused on viral vectors and other complex biologics. After joining Paragon in 2002, Philip held positions of increasing scope and responsibility, including appointments as the Principal Scientist and VP of Business Development. Philip obtained a Bachelor of Arts in Chemistry from Johns Hopkins University and a Ph.D. in Pharmacology from the University of Maryland Medical School.*

FRI
MAR 8
2024

11:00~12:00

CIRA
AUDITORIUM

## CONTACT

Kelvin K. Hui, Ph.D.
Research Promoting Office
87053
kelvin.hui@cira.kyoto-u.ac.jp

登録
**Registration**